Skip to main content
Top
Published in: Diagnostic Pathology 1/2024

Open Access 01-12-2024 | Ovarian Cancer | Research

A risk model based on 10 ferroptosis regulators and markers established by LASSO-regularized linear Cox regression has a good prognostic value for ovarian cancer patients

Authors: Tingchuan Xiong, Yinghong Wang, Changjun Zhu

Published in: Diagnostic Pathology | Issue 1/2024

Login to get access

Abstract

Ovarian cancer is the deadliest gynecologic cancer due to its high rate of recurrence and limited early diagnosis. For certain patients, particularly those with recurring disorders, standard treatment alone is insufficient in the majority of cases. Ferroptosis, an iron- and ROS (reactive oxygen species)-reliant cell death, plays a vital role in the occurrence of ovarian cancer. Herein, subjects from TCGA-OV were calculated for immune scores using the ESTIMATE algorithm and assigned into high- (N = 185) or low-immune (N = 193) score groups; 259 ferroptosis regulators and markers were analyzed for expression, and 64 were significantly differentially expressed between two groups. These 64 differentially expressed genes were applied for LASSO-regularized linear Cox regression for establishing ferroptosis regulators and a markers-based risk model, and a 10-gene signature was established. The ROC curve indicated that the risk score-based curve showed satisfactory predictive efficiency. Univariate and multivariate Cox risk regression analyses showed that age and risk score were risk factors for ovarian cancer patients’ overall survival; patients in the high-risk score group obtained lower immune scores. The Nomogram analysis indicated that the model has a good prognostic performance. GO functional enrichment annotation confirmed again the involvement of these 10 genes in ferroptosis and immune activities. TIMER online analysis showed that risk factors and immune cells were significantly correlated. In conclusion, the risk model based on 10 ferroptosis regulators and markers has a good prognostic value for ovarian cancer patients.
Literature
3.
go back to reference Cortez AJ, et al. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17–38.PubMedCrossRef Cortez AJ, et al. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17–38.PubMedCrossRef
7.
go back to reference Yu H, et al. Ferroptosis, a new form of cell death, and its relationships with tumourous Diseases. J Cell Mol Med. 2017;21(4):648–57.PubMedCrossRef Yu H, et al. Ferroptosis, a new form of cell death, and its relationships with tumourous Diseases. J Cell Mol Med. 2017;21(4):648–57.PubMedCrossRef
8.
go back to reference Latunde-Dada GO. Ferroptosis: role of lipid peroxidation, iron and ferritinophagy. Biochim Biophys Acta Gen Subj. 2017;1861(8):1893–900.PubMedCrossRef Latunde-Dada GO. Ferroptosis: role of lipid peroxidation, iron and ferritinophagy. Biochim Biophys Acta Gen Subj. 2017;1861(8):1893–900.PubMedCrossRef
10.
go back to reference Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234–45.PubMedPubMedCentralCrossRef Yang WS, Stockwell BR. Synthetic lethal screening identifies compounds activating iron-dependent, nonapoptotic cell death in oncogenic-RAS-harboring cancer cells. Chem Biol. 2008;15(3):234–45.PubMedPubMedCentralCrossRef
11.
go back to reference Zhou N, Bao J. FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020;2020:baaa021.PubMedCrossRef Zhou N, Bao J. FerrDb: a manually curated resource for regulators and markers of ferroptosis and ferroptosis-disease associations. Database (Oxford). 2020;2020:baaa021.PubMedCrossRef
12.
go back to reference Derry PJ, et al. Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s Disease from a ferroptosis perspective. Prog Neurobiol. 2020;184:101716.PubMedCrossRef Derry PJ, et al. Revisiting the intersection of amyloid, pathologically modified tau and iron in Alzheimer’s Disease from a ferroptosis perspective. Prog Neurobiol. 2020;184:101716.PubMedCrossRef
13.
go back to reference Li Y, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 2019;26(11):2284–99.PubMedPubMedCentralCrossRef Li Y, et al. Ischemia-induced ACSL4 activation contributes to ferroptosis-mediated tissue injury in intestinal ischemia/reperfusion. Cell Death Differ. 2019;26(11):2284–99.PubMedPubMedCentralCrossRef
14.
go back to reference Li Y, et al. Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury. Cell Death Differ. 2020;27(9):2635–50.PubMedPubMedCentralCrossRef Li Y, et al. Inhibitor of apoptosis-stimulating protein of p53 inhibits ferroptosis and alleviates intestinal ischemia/reperfusion-induced acute lung injury. Cell Death Differ. 2020;27(9):2635–50.PubMedPubMedCentralCrossRef
15.
go back to reference Friedmann Angeli JP, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute Renal Failure in mice. Nat Cell Biol. 2014;16(12):1180–91.PubMedCrossRef Friedmann Angeli JP, et al. Inactivation of the ferroptosis regulator Gpx4 triggers acute Renal Failure in mice. Nat Cell Biol. 2014;16(12):1180–91.PubMedCrossRef
16.
go back to reference Cori CF, Cori GT. The carbohydrate metabolism of tumors: II. Changes in the sugar, lactic acid, and CO2-combining power of blood passing through a Tumor. J Biol Chem. 1925;65(2):397–405.CrossRef Cori CF, Cori GT. The carbohydrate metabolism of tumors: II. Changes in the sugar, lactic acid, and CO2-combining power of blood passing through a Tumor. J Biol Chem. 1925;65(2):397–405.CrossRef
17.
go back to reference Warburg O, Minami S. Versuche an überlebendem carcinom-gewebe. J Mol Med. 1923;2(17):776–7. Warburg O, Minami S. Versuche an überlebendem carcinom-gewebe. J Mol Med. 1923;2(17):776–7.
18.
go back to reference Gwangwa MV, Joubert AM, Visagie MH. Crosstalk between the Warburg effect, redox regulation and autophagy induction in tumourigenesis. Cell Mol Biol Lett. 2018;23:20.PubMedPubMedCentralCrossRef Gwangwa MV, Joubert AM, Visagie MH. Crosstalk between the Warburg effect, redox regulation and autophagy induction in tumourigenesis. Cell Mol Biol Lett. 2018;23:20.PubMedPubMedCentralCrossRef
19.
go back to reference Diebold L, Chandel NS. Mitochondrial ROS regulation of proliferating cells. Free Radic Biol Med. 2016;100:86–93.PubMedCrossRef Diebold L, Chandel NS. Mitochondrial ROS regulation of proliferating cells. Free Radic Biol Med. 2016;100:86–93.PubMedCrossRef
20.
21.
22.
go back to reference Cerutti PA, Trump BF. Inflammation and oxidative stress in carcinogenesis. Cancer Cells. 1991;3(1):1–7.PubMed Cerutti PA, Trump BF. Inflammation and oxidative stress in carcinogenesis. Cancer Cells. 1991;3(1):1–7.PubMed
23.
go back to reference Yang WH, et al. A TAZ-ANGPTL4-NOX2 Axis regulates ferroptotic cell death and Chemoresistance in epithelial Ovarian Cancer. Mol Cancer Res. 2020;18(1):79–90.PubMedCrossRef Yang WH, et al. A TAZ-ANGPTL4-NOX2 Axis regulates ferroptotic cell death and Chemoresistance in epithelial Ovarian Cancer. Mol Cancer Res. 2020;18(1):79–90.PubMedCrossRef
24.
go back to reference Carbone M, Melino G. Stearoyl CoA desaturase regulates ferroptosis in ovarian cancer offering new therapeutic perspectives. Cancer Res. 2019;79(20):5149–50.PubMedCrossRef Carbone M, Melino G. Stearoyl CoA desaturase regulates ferroptosis in ovarian cancer offering new therapeutic perspectives. Cancer Res. 2019;79(20):5149–50.PubMedCrossRef
26.
go back to reference Drakes ML, Czerlanis CM, Stiff PJ. Immune Checkpoint blockade in gynecologic cancers: state of affairs. Cancers (Basel). 2020;12(11):3301.PubMedCrossRef Drakes ML, Czerlanis CM, Stiff PJ. Immune Checkpoint blockade in gynecologic cancers: state of affairs. Cancers (Basel). 2020;12(11):3301.PubMedCrossRef
27.
go back to reference Pu J, et al. FGF-7 facilitates the process of psoriasis by inducing TNF-alpha expression in HaCaT cells. Acta Biochim Biophys Sin (Shanghai). 2019;51(10):1056–63.PubMedCrossRef Pu J, et al. FGF-7 facilitates the process of psoriasis by inducing TNF-alpha expression in HaCaT cells. Acta Biochim Biophys Sin (Shanghai). 2019;51(10):1056–63.PubMedCrossRef
28.
go back to reference Vasquez MM, et al. Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application. BMC Med Res Methodol. 2016;16(1):154.PubMedPubMedCentralCrossRef Vasquez MM, et al. Least absolute shrinkage and selection operator type methods for the identification of serum biomarkers of overweight and obesity: simulation and application. BMC Med Res Methodol. 2016;16(1):154.PubMedPubMedCentralCrossRef
29.
go back to reference Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612.PubMedCrossRef Yoshihara K, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4(1):2612.PubMedCrossRef
30.
go back to reference Liu L, Lin J, He H. Identification of potential crucial genes associated with the pathogenesis and prognosis of endometrial cancer. Front Genet. 2019;10:373.PubMedPubMedCentralCrossRef Liu L, Lin J, He H. Identification of potential crucial genes associated with the pathogenesis and prognosis of endometrial cancer. Front Genet. 2019;10:373.PubMedPubMedCentralCrossRef
31.
go back to reference Wang X, et al. Identification and validation of m(6)a RNA methylation regulators with clinical prognostic value in papillary thyroid cancer. Cancer Cell Int. 2020;20:203.PubMedPubMedCentralCrossRef Wang X, et al. Identification and validation of m(6)a RNA methylation regulators with clinical prognostic value in papillary thyroid cancer. Cancer Cell Int. 2020;20:203.PubMedPubMedCentralCrossRef
32.
go back to reference Bender R, Lange S. Adjusting for multiple testing–when and how? J Clin Epidemiol. 2001;54(4):343–9.PubMedCrossRef Bender R, Lange S. Adjusting for multiple testing–when and how? J Clin Epidemiol. 2001;54(4):343–9.PubMedCrossRef
33.
go back to reference Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36.PubMedCrossRef Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29–36.PubMedCrossRef
35.
go back to reference Zitvogel L, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73.PubMedCrossRef Zitvogel L, et al. Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73.PubMedCrossRef
36.
go back to reference Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41–51.PubMedCrossRef Yu H, Kortylewski M, Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol. 2007;7(1):41–51.PubMedCrossRef
41.
43.
go back to reference Guo J, et al. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat. 2018;50(2):445–60.PubMedCrossRef Guo J, et al. Ferroptosis: a novel anti-tumor action for cisplatin. Cancer Res Treat. 2018;50(2):445–60.PubMedCrossRef
44.
45.
go back to reference Thomas DD, Wink DA. NOS2 as an emergent player in progression of cancer. Antioxid Redox Signal. 2017;26(17):963–5.PubMedCrossRef Thomas DD, Wink DA. NOS2 as an emergent player in progression of cancer. Antioxid Redox Signal. 2017;26(17):963–5.PubMedCrossRef
47.
go back to reference Nakamura K, et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15(1):78–92.PubMedCrossRef Nakamura K, et al. Exosomes promote ovarian cancer cell invasion through transfer of CD44 to peritoneal mesothelial cells. Mol Cancer Res. 2017;15(1):78–92.PubMedCrossRef
48.
go back to reference Wang Q, et al. Adapalene inhibits ovarian cancer ES-2 cells growth by targeting glutamic-oxaloacetic transaminase 1. Bioorg Chem. 2019;93:103315.PubMedCrossRef Wang Q, et al. Adapalene inhibits ovarian cancer ES-2 cells growth by targeting glutamic-oxaloacetic transaminase 1. Bioorg Chem. 2019;93:103315.PubMedCrossRef
49.
go back to reference Hong T, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient Ovarian cancer. Redox Biol. 2021;42:101928.PubMedPubMedCentralCrossRef Hong T, et al. PARP inhibition promotes ferroptosis via repressing SLC7A11 and synergizes with ferroptosis inducers in BRCA-proficient Ovarian cancer. Redox Biol. 2021;42:101928.PubMedPubMedCentralCrossRef
Metadata
Title
A risk model based on 10 ferroptosis regulators and markers established by LASSO-regularized linear Cox regression has a good prognostic value for ovarian cancer patients
Authors
Tingchuan Xiong
Yinghong Wang
Changjun Zhu
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2024
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/s13000-023-01414-9

Other articles of this Issue 1/2024

Diagnostic Pathology 1/2024 Go to the issue